Mikhail Kosiborod

Research interests

Publications

• Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

  New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2313917

• Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials

  The Lancet · 2024 · https://doi.org/10.1016/s0140-6736(24)00469-0

• Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

  New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2407107

• A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association

  Circulation · 2023 · https://doi.org/10.1161/cir.0000000000001186

• Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2306963

• Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association

  Circulation · 2023 · https://doi.org/10.1161/cir.0000000000001184

• American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update

  Endocrine Practice · 2022 · https://doi.org/10.1016/j.eprac.2022.08.002

• Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

  New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2206286

• Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction

  JACC Heart Failure · 2022 · https://doi.org/10.1016/j.jchf.2021.11.006

• Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial

  European Heart Journal · 2022 · https://doi.org/10.1093/eurheartj/ehac401

• SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials

  The Lancet · 2022 · 10.1016/s0140-6736(22)01429-5

• The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

  Nature Medicine · 2022 · 10.1038/s41591-021-01659-1

• Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

  JAMA · 2020 · https://doi.org/10.1001/jama.2020.1906

• Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1911303

• Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction

  Circulation · 2019 · https://doi.org/10.1161/circulationaha.119.044138

• Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(19)31887-2

• Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(19)31887-2

• 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

  Journal of the American College of Cardiology · 2018 · https://doi.org/10.1016/j.jacc.2018.09.020

• Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs

  Circulation · 2017 · 10.1161/circulationaha.117.029190

• Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association

  Diabetes Care · 2015 · https://doi.org/10.2337/dci15-0012

• Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence

  Circulation · 2015 · https://doi.org/10.1161/cir.0000000000000230

• Excess Mortality among Persons with Type 2 Diabetes

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1504347

• Glycemic Control and Excess Mortality in Type 1 Diabetes

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1408214

• Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials

  Diabetes Care · 2008 · 10.2337/dc08-9026

Current projects

No projects listed.